Cure8 trial brief
Researchers and patients tracking new IBD therapies may care because this is the first human study of a GlaxoSmithKline investigational drug aimed at colitis/ulcerative colitis — an early step that could lead to future patient trials if results are favorable.
For most people with Crohn’s or ulcerative colitis, this trial does not change clinical care now because it tests safety in healthy volunteers rather than effectiveness in patients.
Researchers, clinicians, and patients interested in IBD drug development and early-phase clinical trials; people who follow investigational biologic/small-molecule programs for ulcerative colitis/colitis.
This is a Phase 1 first-in-human trial testing GSK4528287, an experimental drug being developed by GlaxoSmithKline for inflammatory bowel diseases (the registry lists ulcerative colitis and colitis).
The study will give single ascending doses of GSK4528287 or placebo to healthy adult volunteers to assess safety, tolerability, blood drug levels (pharmacokinetics), and target engagement; planned enrollment is about 48 participants. The headline focus is early human safety and how the drug behaves in the body — not efficacy in people with IBD.
Primary outcomes are adverse events, serious adverse events, and clinically significant changes in labs, vitals, and telemetry, assessed through about 351 days of follow-up. If you follow IBD drug development, this is an early-stage trial that could support later patient trials if safety and target engagement are acceptable.
This registry entry does not report results.
This is a Phase 1, first-in-human single-ascending-dose study in healthy adult volunteers; the registry entry lists safety and PK/target engagement endpoints but does not contain trial results. Early-phase safety trials commonly enroll healthy volunteers and are designed to inform whether later patient-focused studies are appropriate.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
